Inhaled corticosteroids and COVID-19-related mortality: confounding or clarifying?

Inhaled corticosteroids (ICSs) are the mainstay of anti-inflammatory therapy for asthma and chronic obstructive pulmonary disease (COPD).1,2 Studies have shown worse outcomes in patients with COVID-19 who have been admitted to hospital and have comorbidities including chronic lung diseases.3–5 Whether ICSs protect against COVID-19 or contribute to worse outcomes from COVID-19 has been debated.6,7…

Read the full article here

Related Articles